Myopia Control Lens
Researchers at the Hong Kong Polytechnic University collaborated with Hoya Vision Care, based on the myopic defocus theory, have developed a new myopia control spectacle lens, DIMS (Defocus Incorporated Multiple Segments) lens. The myopic defocus theory indicates that myopia progression can be controlled by providing clear vision and constant myopic defocus simultaneously. Research team designed this myopia control lens by incorporating many micro-lenses over the lens surface, so that the “eye still experiences a constant amount of myopic defocus” as the eye moves around different regions of the lens. It was proven in a two-year clinical trial with a sample of 160 children aged 8 to 13. The result shows that this DIMS lens technology works to curb myopic progression by up to 59%.
DIMS spectacle lenses were made commercially available under the brand name MiyoSmart. It won the Grand Prize (Overall Championship), Grand Award and Gold Medal with the Congratulations of Jury at the 46th International Exhibition of Inventions of Geneva.
MiyoSmart is an innovative spectacle lens for myopia control developed by Hoya together with its partner, The Hong Kong Polytechnic University. Based on a two-year clinical trial results, MiyoSmart is proven to curb myopia progression by up to 59% and halt myopia progression by 21.5% with its award-winning D.I.M.S. (Defocus Incorporated Multiple Segments) technology.
MiyoSmart with D.I.M.S. technology is comprised of a central optical zone for correcting refractive error and multiple defocus segments evenly surrounding the central zone (extending to the mid-periphery) of the lens to control myopia progression. This provides clear vision and myopic defocus simultaneously at all viewing distances. The lens makes use of the natural homeostatic mechanism known as “emmetropisation”, whereby the eyeball adapts and shapes to receive focused images as it does for normal vision.
– Curb myopia progression in average by 59%
– Slow axial eye growth in average by 60%
– Halts myopia progression in 21.5% of Children
( Information provided by The Hong Kong Polytechnic University and Hoya Vision Care)